TMPRSS2 and prostate carcinoma: For example, TMPRSS2‐ERG fusions are observed in 40% of prostate cancers (Cancer Genome Atlas Network, 2015b), and p1/q19 chromosomal co‐deletions are observed in 30% of lower‐grade gliomas (Brat et al,2015).